Alliance Wealth Advisors LLC UT Increases Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Alliance Wealth Advisors LLC UT boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,896 shares of the company’s stock after purchasing an additional 131 shares during the quarter. Alliance Wealth Advisors LLC UT’s holdings in Medpace were worth $888,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Riverbridge Partners LLC grew its holdings in Medpace by 7.1% in the fourth quarter. Riverbridge Partners LLC now owns 652,384 shares of the company’s stock worth $199,975,000 after purchasing an additional 43,197 shares during the period. Invesco Ltd. grew its holdings in shares of Medpace by 67.6% during the third quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after buying an additional 246,775 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Medpace by 312.6% during the third quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after buying an additional 319,210 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Medpace by 4.0% during the third quarter. Northern Trust Corp now owns 241,202 shares of the company’s stock valued at $58,402,000 after buying an additional 9,192 shares during the last quarter. Finally, AQR Capital Management LLC grew its holdings in shares of Medpace by 55.7% during the third quarter. AQR Capital Management LLC now owns 183,310 shares of the company’s stock valued at $44,385,000 after buying an additional 65,614 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and increased their price target for the company from $282.00 to $452.00 in a report on Thursday, February 15th. StockNews.com upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Tuesday. Robert W. Baird increased their price target on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a report on Wednesday. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and raised their target price for the stock from $340.00 to $450.00 in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $443.00.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 102 shares of the stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the transaction, the vice president now directly owns 15,181 shares in the company, valued at $6,117,943. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO August J. Troendle sold 100,000 shares of the firm’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the sale, the chief executive officer now directly owns 4,833,019 shares in the company, valued at approximately $1,995,940,186.62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Susan E. Burwig sold 102 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the sale, the vice president now owns 15,181 shares in the company, valued at $6,117,943. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 189,340 shares of company stock worth $76,651,647. Company insiders own 20.30% of the company’s stock.

Medpace Trading Up 1.6 %

MEDP stock traded up $6.16 on Friday, hitting $395.93. The company had a trading volume of 144,681 shares, compared to its average volume of 240,981. Medpace Holdings, Inc. has a 12-month low of $189.30 and a 12-month high of $421.00. The stock has a market cap of $12.27 billion, a price-to-earnings ratio of 40.36, a P/E/G ratio of 1.94 and a beta of 1.38. The stock’s 50-day simple moving average is $397.83 and its 200 day simple moving average is $325.15.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.92% and a return on equity of 59.74%. The business had revenue of $511.00 million for the quarter, compared to the consensus estimate of $512.39 million. During the same period last year, the firm earned $2.27 earnings per share. The company’s quarterly revenue was up 17.7% on a year-over-year basis. Research analysts forecast that Medpace Holdings, Inc. will post 11.23 earnings per share for the current year.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.